Fulcrum Therapeutics (FULC) Income from Continuing Operations (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Income from Continuing Operations of 34984000.0 for Q2 2026, up 16.65% year-over-year from 29991165.68 in Q2 2025, and up 29.98% quarter-over-quarter from 49965473.0 in Q1 2026.
Powered by 
Analysis
Fulcrum Therapeutics (FULC) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Income from Continuing Operations for 9 consecutive years, with 34984000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Income from Continuing Operations rose 16.65% year-over-year to 34984000.0; the TTM figure through Jun 2026 stood at 234095687.0 (down 78.59% YoY), while the FY2025 annual figure was 161231000.0, down 119.71% from the prior year.
- Income from Continuing Operations grew to 34984000.0 in Q2 2026 per FULC's latest filing, from 49965473.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 40216583.0 in Q2 2024 and bottomed at 93996741.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 42797378.61 across 5 years, with a median of 41579000.0 in 2023.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations soared 197.39% — and 2025, when it slumped 236.18%.
- Fulcrum Therapeutics' Income from Continuing Operations stood at 29858160.0 in 2022, then slumped by 44.37% to 43106074.0 in 2023, then soared by 41.93% to 25031463.0 in 2024, then plunged by 236.18% to 84151718.0 in 2025, then soared by 58.43% to 34984000.0 in 2026.
- Business Quant data shows FULC's Income from Continuing Operations at 34984000.0 in Q2 2026, 49965473.0 in Q1 2026, and 84151718.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Fulcrum Therapeutics | 293.24 Mn | 293.24 Mn | - | -26.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -26.18 Mn |
| Mar 31, 2026 | -22.87 Mn |
| Dec 31, 2025 | -20.33 Mn |
| Sep 30, 2025 | -19.60 Mn |
| Jun 30, 2025 | -17.30 Mn |
| Mar 31, 2025 | -20.46 Mn |
| Dec 31, 2024 | -16.57 Mn |
| Sep 30, 2024 | -21.70 Mn |
| Jun 30, 2024 | 52.56 Mn |
| Mar 31, 2024 | -30.13 Mn |
| Dec 31, 2023 | -24.76 Mn |
| Sep 30, 2023 | -24.02 Mn |
| Jun 30, 2023 | -27.84 Mn |
| Mar 31, 2023 | -27.79 Mn |
| Dec 31, 2022 | -26.14 Mn |
| Sep 30, 2022 | -23.74 Mn |
| Jun 30, 2022 | -34.21 Mn |
| Mar 31, 2022 | -26.69 Mn |
| Dec 31, 2021 | -24.09 Mn |
| Sep 30, 2021 | -20.72 Mn |